Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CannTrust Holdings Inc CNTTQ

CannTrust Holdings Inc is engaged in the business of producing and distributing medical cannabis in Canada. Its facility is located at Vaughan, Ontario in Canada. Its brands include LIIV, ESCAPE, SYNR.G and Peak Leaf.


GREY:CNTTQ - Post by User

Bullboard Posts
Comment by BIBI123on Oct 11, 2018 9:27am
167 Views
Post# 28779741

RE:RE:Price target upgraded by Beacon securities, BUY, PT $21

RE:RE:Price target upgraded by Beacon securities, BUY, PT $21
retiredcf wrote:

CannTrust Holdings Inc. (TRST-T) is "one of a handful of producers positioned to excel" in the early days of the legal marijuana market, according to Beacon Securities analyst Russell Stanley.

"We believe that shelf space has become the new battleground in the Canadian market," he said. "On a mid/long-term basis, winning this battle will require the capacity to produce on a large-scale basis in terms of both volume and product breadth. Moreover, as additional production capacity comes online, we expect price compression for standard dried flower products, which will make the development and commercialization of higher value products (e.g. oils/extracts, capsules and creams in today's market, and vape pens, edibles and beverages for tomorrow's) increasingly important.

"TRST already excels on both fronts, and we expect that to continue. The Company is already the market leader in terms of revenue mix, as 60 per cemt of last quarter's cannabis revenue came from the sale of oils/extracts. This weighting is approximately 2 times the weighted average amongst major producers of 30 per cent, and puts CannTrust well ahead of its closest peers at the 45-per-cent level. We believe this demonstrates the Company's ability to deliver and achieve market penetration for value-added products. Through partnerships with Apotex and Club Coffee L.P., TRST is well positioned to continue developing and commercializing higher value products that should help the Company further penetrate both the recreational and medical markets."

In a research report released Thursday, Mr. Stanley initiated coverage of the stock with a "buy" rating.

"CannTrust is already one of the largest producers in the space, with a current annualized cultivation capacity of 50,000 kilograms, and a fully-funded Phase 3 expansion on track to take that to 100,000 kilograms plus," he said. "This puts TRST in the upper tier of producers in terms of scale, which we believe will be important to provincial buying authorities as it helps ensure reliability of supply.

"Importantly, CannTrust has already secured supply agreements with eight provinces, the only notable exceptions to date being Quebec and Saskatchewan. The Company also recently announced entering a letter of intent with Canada's largest beverage alcohol broker of premium spirits, wine and beer brands (Breakthru Beverage Group)."

Seeing multiple potential catalysts for the stock, Mr. Stanley set a target price of $21, exceeding the consensus of $16.11.

"We believe that a U.S. exchange listing is a likely initiative for the Company in the near-term," he said. "With just three current U.S.-listed peers trading at an average of 99 times EV/calendar 2020 estimated EBITDA based on consensus estimates (ranging from 37 times to 163 times), the multiple lift could be significant. With an existing relationship with Apotex covering the pharmaceutical space, we expect CannTrust to develop similar partnerships for other verticals.

"Finally, we believe that CannTrust's fully-funded large scale production platform, leadership in higher value products, and supply agreements in eight provinces make CannTrust an ideal acquisition target, particularly for companies from other industries looking for a platform transaction to enter the space."

 

Awesome! Thank you retiredcf for this.
Bibi

Bullboard Posts